Emergent Biosolutions Inc  

(Public, NYSE:EBS)   Watch this stock  
Find more results for EBS
40.30
+0.04 (0.10%)
After Hours: 40.30 0.00 (0.00%)
Oct 19, 4:46PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 39.54 - 40.44
52 week 24.47 - 41.46
Open 39.85
Vol / Avg. 0.00/265,909.00
Mkt cap 1.66B
P/E 29.36
Div/yield     -
EPS 1.37
Shares 41.21M
Beta 1.30
Inst. own 88%
Dec 7, 2017
Emergent BioSolutions Inc Analyst & Investor Day - 8:30AM EST - Add to calendar
Dec 4, 2017
Emergent BioSolutions Inc at Singular Research Best of the Uncovered Conference Add to calendar
Nov 15, 2017
Emergent BioSolutions Inc at Three Part Advisors Southwest IDEAS Investor Conference Add to calendar
Nov 2, 2017
Q3 2017 Emergent BioSolutions Inc Earnings Call - 5:00PM EDT - Add to calendar
Nov 2, 2017
Q3 2017 Emergent BioSolutions Inc Earnings Release - 4:00PM EDT - Add to calendar
Sep 25, 2017
Emergent BioSolutions Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 20, 2017
Emergent BioSolutions Inc at Singular Research Chicago Midwestern Values
Sep 7, 2017
Emergent BioSolutions Inc at Wells Fargo Healthcare Conference
Aug 31, 2017
Emergent BioSolutions Inc at Three Part Advisors Midwest IDEAS Investor Conference
Aug 3, 2017
Q2 2017 Emergent BioSolutions Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin 4.58% 12.79%
Operating margin 8.46% 21.59%
EBITD margin - 29.41%
Return on average assets 1.93% 6.23%
Return on average equity 3.01% 9.95%
Employees 1,098 -
CDP Score - -

Address

400 Professional Dr Ste 400
GAITHERSBURG, MD 20879-3457
United States - Map
+1-240-6313200 (Phone)
+1-240-6313203 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Officers and directors

Fuad El-Hibri Executive Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Daniel J. Abdun-Nabi President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Robert G. Kramer Sr. Chief Financial Officer, Executive Vice President, Administration, Treasurer
Age: 59
Bio & Compensation  - Reuters
Adam Havey Executive Vice President - Business Operations
Age: 46
Bio & Compensation  - Reuters
Ronald B. Richard Lead Independent Director
Age: 61
Bio & Compensation  - Reuters
Sue Bailey M.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Zsolt Harsanyi Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Jerome M. Hauer Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
George A. Joulwan USA Independent Director
Age: 77
Bio & Compensation  - Reuters